Progyny (NASDAQ:PGNY) EVP Sells $29,998.98 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 1,199 shares of Progyny stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total value of $29,998.98. Following the completion of the transaction, the executive vice president directly owned 83,316 shares in the company, valued at $2,084,566.32. This trade represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

• On Thursday, June 4th, Allison Swartz sold 599 shares of Progyny stock. The stock was sold at an average price of $25.08, for a total value of $15,022.92.

Progyny Price Performance

Progyny stock traded up $0.38 during trading hours on Friday, reaching $25.86. The company had a trading volume of 1,207,696 shares, compared to its average volume of 1,553,521. The company has a 50-day moving average price of $20.42 and a 200 day moving average price of $22.27. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 33.58, a P/E/G ratio of 1.33 and a beta of 1.03. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. During the same period in the previous year, the firm earned $0.17 EPS. The business’s quarterly revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts expect that Progyny, Inc. will post 1.12 earnings per share for the current year.

Progyny declared that its board has initiated a stock buyback plan on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Truist Financial boosted their target price on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, May 11th. BTIG Research reduced their target price on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Barclays boosted their target price on Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Citigroup restated an “outperform” rating on shares of Progyny in a report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System lifted its holdings in shares of Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after purchasing an additional 457 shares in the last quarter. Teza Capital Management LLC lifted its holdings in shares of Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after purchasing an additional 516 shares in the last quarter. Aristides Capital LLC lifted its holdings in shares of Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after purchasing an additional 528 shares in the last quarter. Leibman Financial Services Inc. lifted its holdings in shares of Progyny by 1.2% during the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock valued at $1,192,000 after purchasing an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP lifted its holdings in shares of Progyny by 4.3% during the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after purchasing an additional 531 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.